| monoclonal antibody | ustinumab (Ustekinumab, abbreviated as: UST) is a fully human IgG1k monoclonal antibody that can bind to the p40 subunit of IL-12/23. It is the only biological agent approved for the treatment of IL-12/23 in the world, with low immunogenicity and incidence of anti-antibody and high safety. Global indications (2008 European listing, approved for CD indications in 46 countries). At present, my country was approved for Crohn's disease indications in March 202020. Ukinumab is suitable for traditional treatment or tumor necrosis factor alpha (TNFα) antagonists (infliximab, adalimumab) Adult patients with moderate to severe active Crohn's disease (CD) who have insufficient response, loss of response, or cannot tolerate. |
| pharmacological action | ustinumab is a fully humanized monoclonal IgG1 antibody of p40, the common subunit of IL-12 and IL-23, which can prevent these two inflammatory mediators from binding to IL-12Rβ1 receptors on the surfaces of T lymphocytes, NKC and APCs, thus blocking the differentiation of virgin T lymphocytes into Th1 and Th17. In psoriasis treatment studies, ustinumab is slowly absorbed into the systemic circulation after a single dose of subcutaneous injection, and the median time to peak is between 7-14 days after administration, and the dose range is about 24mg to 240mg. The median half-life of ustinumab is about 3 weeks, regardless of the route of administration and single or multiple administrations. There is no evidence that the concentration of urinumab in serum will accumulate over time. In 2009, the British National Health and Medical Quality Standards Agency approved Ulinumab for the treatment of mild to severe psoriasis, and the US Food and Drug Administration also approved the drug to be marketed in the United States. At present, this drug has been approved for the treatment of psoriasis in 74 countries. The Guidelines for Psoriasis and Psoriatic Arthritis issued by the American Academy of Dermatology (AAD) in 2011 recommend ustinumab as a first-line drug for the treatment of adult plaque psoriasis. |